Abstract-A practical procedure for evaluating uricosuric agents was demonstrated using clearance experiments with potassium oxonate-treated rats. The fractional excretion value of uric acid showed a reabsorptive net flux of uric acid in the renal tubules of the animal, though the value was obviously higher than those of primates such as men, chimpanzees and cebus monkeys. However, the rats responded well to uricosuric drugs and diuretics. Probenecid and uricosuric diuretics such as tienilic acid induced hyper uricosuria due to the increase of fractional excretion of uric acid and/or the increase of the filtered amount of uric acid with the rise of plasma uric acid. On the other hand, furosemide had no effect on uric acid excretion at a low dose with moderate diuresis, while a higher dose decreased the fractional excretion of uric acid with elevation of plasma uric acid. Benzothiazides were also uricosuric at the lower doses, but the high dose, as in the case of the so-called uricosuric drugs, had no effect on the uric acid excretion and plasma uric acid level. Thus, oxonate-treated rats were useful for evaluating drug effects on uric acid excretion.
Because of species differences in the metabolism and excretion of uric acid, animal experiments have contributed little to the evaluation of drug activities on the renal handling of uric acid, except for those using primates such as chimpanzees and cebus monkeys. The urinary excretion of uric acid, however, has been well studied with various nonhuman mammalia in order to find useful animals for the evaluation, resulting in some successful examples (1) . The rat is such an animal because it shows a reabsorptive net flux of uric acid in the renal tubules, though the animal handles uric acid by both hepatic metabolism and renal excretion. On the other hand, useful inhibitors of urate oxidase have already been developed to create the disease model of hyperuricemia (2) (3) (4) , but the inhibitor-treated animals have not been utilized enough for evaluating uricosuric agents. A practical procedure for evaluating the drugs with potassium oxonate treated rats is reported here.
Materials and Methods
Ten-week-old male Slc-Wistar rats were used. To determine uric acid and inulin clearance, the animals were given potassium oxonate, 250 mg/kg i.p., and then the right femoral artery, left femoral vein and urinary bladder were cannulated for blood collection, infusion and urine collection, respectively, under anesthesia with sodium pentobarbital, 50 mg/kg i.p., within 2 hr after the adminis tration of oxonate. The same dose of oxonate was given again just 2 hr after the first administration, and then 60% urethane, 2 ml/kg, and 15% inulin, 4 ml/kg, were administered subcutaneously. The animals were then infused with 4% mannitol-1.5% inulin-0.9% sodium chloride solution at the flow rate of 0.1 ml/min on a hot plate at & K. IWAKI 30°C. After equilibration for 40 min, 0.2 ml of arterial blood was collected six times at 20 min intervals, and five 20-min urine samples were collected. Plasma was separated im mediately after the blood collection, and the plasma and urine samples were stored in a freezer.
Test drugs were suspended into 1 % gum arabic solution and given 2 ml/kg i.p. just after the first urine collection. To determine the free-type ratio of plasma uric acid, rats were given potassium oxonate, 250 mg/kg i.p., twice with a 2-hr interval; then arterial blood from the aorta was collected under anesthesia with sodium pentobarbital 1 hr later. Plasma was separated immediately after the blood collection and then filtered with an ultrafiltration membrane cone (CENTRIFLO, Amicon). Plasma and urinary uric acid were deter mined by the method described previously (5 First, the experimental con ditions were established as described in Methods through trial and error in order to obtain a reabsorptive net flux of uric acid in the renal tubules with well-controlled levels of the urine volume, urine-excreted amount of uric acid, plasma uric acid and glomerular filtration rate (Table 1) .
Potassium oxonate was given 250 mg/kg i.p. according to Johnson et al. (2) . The first administration of the agent progressively increased plasma uric acid and urine volume, while the second treatment after a 2-hr interval retained the high levels of plasma uric acid and urine volume for 2 hr or more. Osmotic diuresis with mannitol was attempted to produce a urine volume corresponding to about 70% of the infused solution.
Urethane was available as a long-acting anesthetic.
The fractional excretion of uric acid (FE,,,,.,,, acid) was 0.6-0.7 under the established conditions, while the free-type ratio of plasma uric acid in oxonate-treated rats was 97% as seen in Table 2 .
Effects of probenecid:
The practicality of the established procedure was evaluated with probenecid first. As presented in Table  3 , probenecid slightly increased the FEuric acid value at 20 mg/kg, and it was more uricosuric at doses of more than 50 mg/kg. However, the higher doses also increased plasma uric acid, and the effect was dose-dependent.
Thus, probenecid increased the urine excreted amount of uric acid in response to the doses in oxonate-treated rats through increases of both the filtered amount and fractional excretion. The urine volume also increased slightly at 50 mg/kg of the drug, but the effect was not dependent on the dose.
Effects of uricosuric diuretics: As shown in Table 4 , tienilic acid showed similar effects to those of probenecid.
More diuretic com pounds, indanylacetic acid (MK-196) and 6,7-dichloro-2,3-di hydro-5 (2-thienyl carbonyl)-2-benzofurancarboxylic acid, also increased urinary uric acid with elevation of plasma uric acid, but had no effect on the FEuric acid level.
The effects of these drugs were studied again under treatment with pyrazinoic acid to inhibit the tubular secretion of uric acid according to Frankfurt and Weinman (7) . Pyrazinoic acid at 50 mg/kg i.p. was given first followed by oxonate and then a 0.4% concentration of pyrazinoic acid was added to the infused solution as the sustaining dose. As presented in Table 5 The effects of furosemide and trichlormethiazide were studied with two doses: one was the same as those of the uricosuric drugs, and the other was the dose for producing moderate diuresis.
As shown in Table 6 , 1.0 mg/kg of furosemide had no effect on uric acid excretion, while 50 mg/kg obviously decreased the FEuric acid level with the rise of plasma uric acid.
On the other hand, trichlormethiazide showed an apparent uricosuric effect at the lower dose, but not at the high dose as can be seen from Table 7 . 
Discussion
The net flux of uric acid in the renal tubules of rats has been well studied, but the results are inconsistent (1, (8) (9) (10) (11) (12) reported that the rats infused with oxonate and mannitol showed a high level of FEuric acid like that of urate-loaded animals. The level and the overall function in the kidneys were similar to those of the present study. On the other hand, Boundry showed the uricosuric effect of probenecid in the rat, but failed to show the effect with a high concentration of plasma uric acid by urate-loading (13) . However, the oxonate-treated rats in the present study responded well to probenecid in spite of the high levels of plasma uric acid and FEuric acid. The uricosuric effect of tienilic acid was also observed with the animals. Recent work with chimpanzees has offered some compounds that are derivatives of phenoxyacetic acid and benzofuran carboxylic acid which are both uricosuric and diuretic (14, 15) . These compounds being more diuretic than tienilic acid also increased the urine-excreted amount of uric acid in oxonate-treated rats, but did not change the FEuric acid level. As previously demonstrated (5), probenecid and tienilic acid elevated the plasma uric acid in conscious oxonate-treated rats and also in rats loaded with uric acid under the treatments with allopurinol and oxonate to inhibit both the production and metabolism of uric acid. These observations suggested that the rise of plasma uric acid caused by some uricosuric drugs in oxonate-treated rats was not always dependent upon the product stimu lation of uric acid. Although the cause was not clear, the elevation of plasma uric acid resulted in a hyperuricosuria due to an increase of the filtered amount of uric acid. The two uricosuric diuretics, which had no effect on the FEuric acid level, showed such a uricosuric effect at 50 mg/kg, but not at doses lower than 10 mg/kg. According to Frankfurt and Weinman (7), a lowering effect of pyrazinoic acid on the FEuric acid level was expected, though the effect was slight. However, the fact that the animals treated with pyrazinoic acid showed an obvious rise of FEuric acid upon treatment with the uricosuric diuretics was appreciable for the evaluation of such drugs. These drugs had no effect on FEuric acid level in oxonate treated rats (Table 4) , while an obvious increase of the level was demonstrated under the treatment with pyrazinoic acid (Table 5) . On the other hand, these uricosuric diuretics apparently increased the FEuric acid level in chimpanzees (14, 15), for which FEuric acid level was lower than that of oxonate-treated rats. Accordingly, it is probable that the increase of FEuric acid level in oxonate-treated rats can not be observed in the treatment with uricosuric drugs containing a relatively potent effect on the inhibition of tubular secretion of uric acid, because the animals show a relatively large amount of the secretion in the renal handling of uric acid as seen from the high level of FEuric acid.
The rise of plasma uric acid caused by the uricosuric diuretics was also recognized in the pyrazinoic acid-treated animals without any modification, though the diuretic effect was less. Thus, although a problem remained as to the cause of the rising plasma uric acid, oxonate-treated rats were useful for evaluating uricosuric drugs.
The animals were also available for studying the effects of diuretics on uric acid excretion. Furosemide had no effect on uric acid excretion other than being moderately diuretic, but the high dose obviously decreased FEuric acid with the rise of plasma uric acid. Nolan and Foulkes (16) reported the inhibition by the drug of the tubular secretion of uric acid in dogs. Accordingly, it is probable that the FEuric acid level of oxonate treated rats is decreased in the treatment with such an inhibitor. The derivative of a uricosuric diuretic, 6,7-dichloro-2,3-dihydro 5-(2-thienylcarbonyl)-2-benzofurancar boxylic acid, was potently diuretic. The 0.5 mg/kg dose showed a diuretic effect similar to that of furosemide, 1.0 mq/kq, and both drugs had no effect on uric acid excretion at these doses. However, the two drugs were obviously different when tested at 50 mg/kg. Both increased plasma uric acid level, but the decrease of FEuric acid level was shown only in the treatment with furosemide. Thus, the FEuric acid level of oxonate-treated rats well responds to both effects on tubular reabsorption and secretion of uric acid; and therefore, some uricosuric drugs that have an inhibitory effect on both tubular transports of uric acid might have no effect on the FEuric acid level, even if they are uricosuric in men and chimpanzees. This is an important problem in the utility of oxonate-treated rats for evaluating uricosuric drugs; then a further study must be tried on animals treated with pyrazinoic acid to confirm the inhibitory effect of the test drug on the tubular reabsorption of uric acid.
Trichlormethiazide showed an apparent hyperuricosuria at the low doses. The diuretic effect with hyperuricosuria was observed even at 0.005 mg/kg, and also with 0.02-0.5 mg/kg of hydrochlorothiazide, while the 50 mg/kg dose which was as high as those of the so-called uricosuric drugs had no effect on uric acid excretion and the plasma uric acid level. Thus, furosemide and benzothiazides also affected uric acid excretion in oxonate-treated rats, but the effects could only be distinguished from the effects of the so-called uricosuric drugs when they were tested at high doses. 
